CoChat
Sign Up
Cited by 214

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Alterations in cholesterol metabolism as a risk factor for developing Alzheimer’s disease: Potential novel targets for treatment

Loera-Valencia, Raúl, Goikolea, Julen, Parrado-Fernandez, Cristina, Merino-Serrais, Paula, Maioli, Silvia·2019·The Journal of Steroid Biochemistry and Molecular Biology
DOI 10.1016/j.jsbmb.2019.03.003
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jsbmb.2019.03.003

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 149

  1. Prince, 1995, Vascular risk factors and atherosclerosis as risk factors for cognitive decline and dementia, J. Psychosom. Res., 39, 525, 10.1016/0022-3999(95)00025-9 · DOI
  2. Hanon, 2008, Vascular risk factors, cognitve decline, and dementia, Vasc. Health Risk Manag., 4, 363, 10.2147/VHRM.S1839 · DOI
  3. Feldman, 2003, A canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results, Neuroepidemiology, 22, 265, 10.1159/000071189 · DOI
  4. Blennow, 2006, Alzheimer’s disease, Lancet, 368, 387, 10.1016/S0140-6736(06)69113-7 · DOI · Paper page
  5. Isik, 2010, Late onset Alzheimer’s disease in older people, Clin. Interv. Aging, 307, 10.2147/CIA.S11718 · DOI
  6. Qiu, 2005, The age-dependent relation of blood pressure to cognitive function and dementia, Lancet Neurol., 4, 487, 10.1016/S1474-4422(05)70141-1 · DOI · Paper page
  7. Anstey, 2008, Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis, Am. J. Geriatr. Psychiatry, 16, 343, 10.1097/01.JGP.0000310778.20870.ae · DOI
  8. Reitz, 2008, Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment, Dement. Geriatr. Cogn. Disord., 25, 232, 10.1159/000115847 · DOI
  9. Blom, 2013, The influence of vascular risk factors on cognitive decline in patients with dementia: a systematic review, Maturitas, 76, 113, 10.1016/j.maturitas.2013.06.011 · DOI
  10. Kivipelto, 2001, Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study, BMJ, 322, 1447, 10.1136/bmj.322.7300.1447 · DOI · Paper page
  11. Maioli, 2012, Combination of apolipoprotein E4 and high carbohydrate diet reduces hippocampal BDNF and arc levels and impairs memory in young mice, J. Alzheimers Dis., 32, 341, 10.3233/JAD-2012-120697 · DOI
  12. Johnson, 2017, Apolipoprotein E4 mediates insulin resistance-associated cerebrovascular dysfunction and the post-prandial response, J. Cereb. Blood Flow Metab.
  13. Lambert, 2009, Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease, Nat. Genet., 41, 1094, 10.1038/ng.439 · DOI · Paper page
  14. Loera-Valencia, 2018, Targeting alzheimer’s disease with gene and cell therapies, J. Intern. Med., 10.1111/joim.12759 · DOI
  15. Solomon, 2007, Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study, Neurology, 68, 751, 10.1212/01.wnl.0000256368.57375.b7 · DOI
  16. Kivipelto, 2006, Cholesterol as a risk factor for Alzheimer’s disease - epidemiological evidence, Acta Neurol. Scand., 114, 50, 10.1111/j.1600-0404.2006.00685.x · DOI · Paper page
  17. Craft, 2009, The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged, Arch. Neurol., 66, 300, 10.1001/archneurol.2009.27 · DOI · Paper page
  18. Yassine, 2016, Association of serum docosahexaenoic acid with cerebral amyloidosis, JAMA Neurol., 73, 1208, 10.1001/jamaneurol.2016.1924 · DOI · Paper page
  19. Wanamaker, 2015, Cholesterol, statins, and dementia: what the cardiologist should know, Clin. Cardiol., 38, 243, 10.1002/clc.22361 · DOI
  20. McGuinness, 2016, Statins for the prevention of dementia, Cochrane Database Syst. Rev., 10.1002/14651858.CD003160.pub3 · DOI · Paper page
  21. Herrick, 2015, Statins and the liver, Cardiol. Clin., 33, 257
  22. Bayorh, 2005, Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension, Am. J. Hypertens., 18, 1496, 10.1016/j.amjhyper.2005.05.022 · DOI
  23. Huang, 2017, Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer’s disease via modulating the expression of miR-106b, Biomed. Pharmacother., 92, 46, 10.1016/j.biopha.2017.05.060 · DOI
  24. Zhao, 2016, Atorvastatin in improvement of cognitive impairments caused by amyloid beta in mice: involvement of inflammatory reaction, BMC Neurol., 16, 18, 10.1186/s12883-016-0533-3 · DOI
  25. Cramer, 2008, Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study, Neurology, 71, 344, 10.1212/01.wnl.0000319647.15752.7b · DOI
  26. Szwast, 2007, Association of statin use with cognitive decline in elderly African Americans, Neurology, 69, 1873, 10.1212/01.wnl.0000279333.77404.d7 · DOI
  27. Hendrie, 2015, Incident dementia and alzheimer disease in elderly African Americans, Ethn. Dis., 25, 345, 10.18865/ed.25.3.345 · DOI
  28. Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X · DOI · Paper page
  29. Santanello, 1997, Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study, J. Am. Geriatr. Soc., 45, 8, 10.1111/j.1532-5415.1997.tb00971.x · DOI
  30. Muldoon, 2000, Effects of lovastatin on cognitive function and psychological well-being, Am. J. Med., 108, 538, 10.1016/S0002-9343(00)00353-3 · DOI
  31. Muldoon, 2004, Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults, Am. J. Med., 117, 823, 10.1016/j.amjmed.2004.07.041 · DOI
  32. Ohyama, 2006, Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes, J. Biol. Chem., 281, 3810, 10.1074/jbc.M505179200 · DOI
  33. Koudinov, 2001, Essential role for cholesterol in synaptic plasticity and neuronal degeneration, FASEB J., 15, 1858, 10.1096/fj.00-0815fje · DOI
  34. Sodero, 2011, Cellular stress from excitatory neurotransmission contributes to cholesterol loss in hippocampal neurons aging in vitro, Neurobiol. Aging, 32, 1043, 10.1016/j.neurobiolaging.2010.06.001 · DOI
  35. Martin, 2014, Constitutive hippocampal cholesterol loss underlies poor cognition in old rodents, EMBO Mol. Med., 6, 902, 10.15252/emmm.201303711 · DOI
  36. Shie, 2002, Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice, Neuroreport, 13, 455, 10.1097/00001756-200203250-00019 · DOI · Paper page
  37. Mateos, 2009, Activity-regulated cytoskeleton-associated protein in rodent brain is down-regulated by high fat diet in vivo and by 27-hydroxycholesterol in vitro, Brain Pathol., 19, 69, 10.1111/j.1750-3639.2008.00174.x · DOI
  38. Refolo, 2000, Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model, Neurobiol. Dis., 7, 321, 10.1006/nbdi.2000.0304 · DOI · Paper page
  39. Park, 2013, Hypercholesterolemia accelerates amyloid beta-induced cognitive deficits, Int. J. Mol. Med., 31, 577, 10.3892/ijmm.2013.1233 · DOI
  40. Ghribi, 2006, Deposition of iron and beta-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets, J. Neurochem., 99, 438, 10.1111/j.1471-4159.2006.04079.x · DOI · Paper page
  41. Sparks, 1994, Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol, Exp. Neurol., 126, 88, 10.1006/exnr.1994.1044 · DOI · Paper page
  42. Lodeiro, 2017, Aggregation of the inflammatory S100A8 precedes abeta plaque formation in transgenic APP mice: positive feedback for S100A8 and abeta productions, J. Gerontol. A Biol. Sci. Med. Sci., 72, 319
  43. Rahman, 2005, High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice, FEBS Lett., 579, 6411, 10.1016/j.febslet.2005.10.024 · DOI
  44. Guo, 2014, In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer’s disease model, Cell Stem Cell, 14, 188, 10.1016/j.stem.2013.12.001 · DOI
  45. Lutjohann, 1996, Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation, Proc. Natl. Acad. Sci. U. S. A., 93, 9799, 10.1073/pnas.93.18.9799 · DOI · Paper page
  46. Bjorkhem, 1998, Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation, J. Lipid Res., 39, 1594, 10.1016/S0022-2275(20)32188-X · DOI · Paper page
  47. Bjorkhem, 2006, Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain, J. Intern. Med., 260, 493, 10.1111/j.1365-2796.2006.01725.x · DOI
  48. Gamba, 2015, Oxidized cholesterol as the driving force behind the development of Alzheimer’s disease, Front. Aging Neurosci., 7, 10.3389/fnagi.2015.00119 · DOI · Paper page
  49. Saeed, 2014, Effects of a disrupted blood-brain barrier on cholesterol homeostasis in the brain, J. Biol. Chem., 289, 23712, 10.1074/jbc.M114.556159 · DOI
  50. Bjorkhem, 2009, Oxysterols and neurodegenerative diseases, Mol. Aspects Med., 30, 171, 10.1016/j.mam.2009.02.001 · DOI · Paper page
  51. Gold, 2014, 25-Hydroxycholesterol acts as an amplifier of inflammatory signaling, Proc. Natl. Acad. Sci. U. S. A., 111, 10666, 10.1073/pnas.1404271111 · DOI · Paper page
  52. Olkkonen, 2004, Oxysterols and oxysterol binding proteins: role in lipid metabolism and atherosclerosis, Ann. Med., 36, 562, 10.1080/07853890410018907 · DOI
  53. Zhang, 2015, Cholesterol metabolism and homeostasis in the brain, Protein Cell, 6, 254, 10.1007/s13238-014-0131-3 · DOI · Paper page
  54. Guizzetti, 2007, Cholesterol homeostasis in the developing brain: a possible new target for ethanol, Hum. Exp. Toxicol., 26, 355, 10.1177/0960327107078412 · DOI
  55. Meir, 2002, Human sterol 27-hydroxylase (CYP27) overexpressor transgenic mouse model. Evidence against 27-hydroxycholesterol as a critical regulator of cholesterol homeostasis, J. Biol. Chem., 277, 34036, 10.1074/jbc.M201122200 · DOI
  56. Lund, 1999, cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain, Proc. Natl. Acad. Sci., 96, 7238, 10.1073/pnas.96.13.7238 · DOI · Paper page
  57. Testa, 2016, Changes in brain oxysterols at different stages of Alzheimer’s disease: their involvement in neuroinflammation, Redox Biol., 10, 24, 10.1016/j.redox.2016.09.001 · DOI · Paper page
  58. Bogdanovic, 2001, On the turnover of brain cholesterol in patients with Alzheimer’s disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells, Neurosci. Lett., 314, 45, 10.1016/S0304-3940(01)02277-7 · DOI
  59. Wang, 2016, Cholesterol, 24-Hydroxycholesterol, and 27-Hydroxycholesterol as Surrogate Biomarkers in Cerebrospinal Fluid in Mild Cognitive Impairment and Alzheimer’s Disease: A Meta-Analysis, J. Alzheimers Dis., 51, 45, 10.3233/JAD-150734 · DOI
  60. Leoni, 2006, Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment?, Neurosci. Lett., 397, 83, 10.1016/j.neulet.2005.11.046 · DOI
  61. Brown, 2004, Differential expression of cholesterol hydroxylases in Alzheimer’s disease, J. Biol. Chem., 279, 34674, 10.1074/jbc.M402324200 · DOI
  62. Kolsch, 2002, Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer’s disease, Mol. Psychiatry, 7, 899, 10.1038/sj.mp.4001109 · DOI
  63. Wang, 2004, Association between a T/C polymorphism in intron 2 of cholesterol 24S-hydroxylase gene and Alzheimer’s disease in Chinese, Neurosci. Lett., 369, 104, 10.1016/j.neulet.2004.07.020 · DOI
  64. Fernandez Del Pozo, 2006, Polymorphism in the cholesterol 24S-hydroxylase gene (CYP46A1) associated with the APOEpsilon3 allele increases the risk of Alzheimer’s disease and of mild cognitive impairment progressing to Alzheimer’s disease, Dement. Geriatr. Cogn. Disord., 21, 81, 10.1159/000090215 · DOI
  65. Kolsch, 2009, CYP46A1 variants influence Alzheimer’s disease risk and brain cholesterol metabolism, Eur. Psychiatry, 24, 183, 10.1016/j.eurpsy.2008.12.005 · DOI
  66. Chalmers, 2004, APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer’s disease, Neuroreport, 15, 95, 10.1097/00001756-200401190-00019 · DOI
  67. Shibata, 2006, Association studies of cholesterol metabolism genes (CH25H, ABCA1 and CH24H) in Alzheimer’s disease, Neurosci. Lett., 391, 142, 10.1016/j.neulet.2005.08.048 · DOI · Paper page
  68. Borroni, 2004, Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: from risk factors to disease modulators, Neurobiol. Aging, 25, 747, 10.1016/j.neurobiolaging.2003.08.004 · DOI
  69. Li-Hawkins, 2000, Expression cloning of an oxysterol 7alpha-hydroxylase selective for 24-hydroxycholesterol, J. Biol. Chem., 275, 16543, 10.1074/jbc.M001810200 · DOI
  70. Kotti, 2008, Biphasic requirement for geranylgeraniol in hippocampal long-term potentiation, Proc. Natl. Acad. Sci. U. S. A., 105, 11394, 10.1073/pnas.0805556105 · DOI
  71. Kotti, 2006, Brain cholesterol turnover required for geranylgeraniol production and learning in mice, Proc. Natl. Acad. Sci. U. S. A., 103, 3869, 10.1073/pnas.0600316103 · DOI
  72. Maioli, 2013, Is it possible to improve memory function by upregulation of the cholesterol 24S-hydroxylase (CYP46A1) in the brain?, PLoS One, 8, 10.1371/journal.pone.0068534 · DOI
  73. Paul, 2013, The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors, J. Neurosci., 33, 17290, 10.1523/JNEUROSCI.2619-13.2013 · DOI
  74. Famer, 2007, Regulation of alpha- and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway, Biochem. Biophys. Res. Commun., 359, 46, 10.1016/j.bbrc.2007.05.033 · DOI
  75. Hudry, 2010, Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer’s disease, Mol. Ther., 18, 44, 10.1038/mt.2009.175 · DOI
  76. Burlot, 2015, Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology, Hum. Mol. Genet., 24, 5965, 10.1093/hmg/ddv268 · DOI · Paper page
  77. Mast, 2017, Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer’s disease, Neuropharmacology, 123, 465, 10.1016/j.neuropharm.2017.06.026 · DOI
  78. Boussicault, 2016, CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington’s disease, Brain, 139, 953, 10.1093/brain/awv384 · DOI
  79. Palomer, 2016, Aging triggers a repressive chromatin state at bdnf promoters in hippocampal neurons, Cell Rep., 16, 2889, 10.1016/j.celrep.2016.08.028 · DOI
  80. Perez-Canamas, 2016, A diet enriched with plant sterols prevents the memory impairment induced by cholesterol loss in senescence-accelerated mice, Neurobiol. Aging, 48, 1, 10.1016/j.neurobiolaging.2016.08.009 · DOI
  81. Sodero, 2011, Regulation of tyrosine kinase B activity by the Cyp46/cholesterol loss pathway in mature hippocampal neurons: relevance for neuronal survival under stress and in aging, J. Neurochem., 116, 747, 10.1111/j.1471-4159.2010.07079.x · DOI
  82. Cartagena, 2008, Cortical injury increases cholesterol 24S hydroxylase (Cyp46) levels in the rat brain, J. Neurotrauma, 25, 1087, 10.1089/neu.2007.0444 · DOI
  83. Piguet, 2017, Clinical gene therapy for neurodegenerative diseases: past, present, and future, Hum. Gene Ther., 28, 988, 10.1089/hum.2017.160 · DOI
  84. Andersson, 1989, Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme, J. Biol. Chem., 264, 8222, 10.1016/S0021-9258(18)83172-6 · DOI
  85. Cali, 1991, Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis, J. Biol. Chem., 266, 7774, 10.1016/S0021-9258(20)89517-9 · DOI
  86. Babiker, 2005, Patients with atherosclerosis may have increased circulating levels of 27-hydroxycholesterol and cholestenoic acid, Scand. J. Clin. Lab. Invest., 65, 365, 10.1080/00365510510025746 · DOI
  87. Marwarha, 2015, Does the oxysterol 27-hydroxycholesterol underlie Alzheimer’s disease-Parkinson’s disease overlap?, Exp. Gerontol., 68, 13, 10.1016/j.exger.2014.09.013 · DOI
  88. Meaney, 2002, On the rate of translocation in vitro and kinetics in vivo of the major oxysterols in human circulation: critical importance of the position of the oxygen function, J. Lipid Res., 43, 2130, 10.1194/jlr.M200293-JLR200 · DOI
  89. Goldstein, 2006, Protein sensors for membrane sterols, Cell, 124, 35, 10.1016/j.cell.2005.12.022 · DOI · Paper page
  90. Heverin, 2004, Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer’s disease, J. Lipid Res., 45, 186, 10.1194/jlr.M300320-JLR200 · DOI
  91. Meaney, 2007, Novel route for elimination of brain oxysterols across the blood-brain barrier: conversion into 7alpha-hydroxy-3-oxo-4-cholestenoic acid, J. Lipid Res., 48, 944, 10.1194/jlr.M600529-JLR200 · DOI
  92. Schols, 2017, Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial, Brain, 140, 3112, 10.1093/brain/awx273 · DOI
  93. Leoni, 2003, Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers, J. Lipid Res., 44, 793, 10.1194/jlr.M200434-JLR200 · DOI
  94. Stapleton, 1995, A novel cytochrome P450 expressed primarily in brain, J. Biol. Chem., 270, 29739, 10.1074/jbc.270.50.29739 · DOI
  95. Wu, 2013, 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth, Cell Rep., 5, 637, 10.1016/j.celrep.2013.10.006 · DOI
  96. Nelson, 2011, The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver X receptors, Endocrinology, 152, 4691, 10.1210/en.2011-1298 · DOI
  97. Umetani, 2011, 27-Hydroxycholesterol: the first identified endogenous SERM, Trends Endocrinol. Metab., 22, 130, 10.1016/j.tem.2011.01.003 · DOI
  98. DuSell, 2010, The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis, Endocrinology, 151, 3675, 10.1210/en.2010-0080 · DOI
  99. Karuna, 2011, Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism, Atherosclerosis, 214, 448, 10.1016/j.atherosclerosis.2010.10.042 · DOI
  100. Upston, 2002, Disease stage-dependent accumulation of lipid and protein oxidation products in human atherosclerosis, Am. J. Pathol., 160, 701, 10.1016/S0002-9440(10)64890-0 · DOI
  101. Gargiulo, 2015, Relation between TLR4/NF-kappaB signaling pathway activation by 27-hydroxycholesterol and 4-hydroxynonenal, and atherosclerotic plaque instability, Aging Cell, 14, 569, 10.1111/acel.12322 · DOI
  102. Radhakrishnan, 2007, Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig, Proc. Natl. Acad. Sci. U. S. A., 104, 6511, 10.1073/pnas.0700899104 · DOI · Paper page
  103. Sever, 2003, Insig-dependent ubiquitination and degradation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniol, J. Biol. Chem., 278, 52479, 10.1074/jbc.M310053200 · DOI
  104. Ismail, 2017, 27-Hydroxycholesterol impairs neuronal glucose uptake through an IRAP/GLUT4 system dysregulation, J. Exp. Med., 214, 699, 10.1084/jem.20160534 · DOI
  105. Heverin, 2015, 27-hydroxycholesterol mediates negative effects of dietary cholesterol on cognition in mice, Behav. Brain Res., 278, 356, 10.1016/j.bbr.2014.10.018 · DOI
  106. Mateos, 2011, Upregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimer’s disease, J. Alzheimers Dis., 24, 669, 10.3233/JAD-2011-101512 · DOI
  107. Cedazo-Minguez, 2011, Plasma cholesterol and risk for late-onset Alzheimer’s disease, Expert Rev. Neurother., 11, 495, 10.1586/ern.11.36 · DOI
  108. Mateos, 2011, Side chain-oxidized oxysterols regulate the brain renin-angiotensin system through a liver X receptor-dependent mechanism, J. Biol. Chem., 286, 25574, 10.1074/jbc.M111.236877 · DOI
  109. Merino-Serrais, 2018, 27-hydroxycholesterol induces aberrant morphology and synaptic dysfunction in hippocampal neurons, Cereb. Cortex
  110. Lujan, 1996, Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus, Eur. J. Neurosci., 8, 1488, 10.1111/j.1460-9568.1996.tb01611.x · DOI
  111. Shafaati, 2011, Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer’s patients with the Swedish APP 670/671 mutation, J. Lipid Res., 52, 1004, 10.1194/jlr.M014548 · DOI
  112. Liu, 2016, Relationship between oxysterols and mild cognitive impairment in the elderly: a case-control study, Lipids Health Dis., 15, 177, 10.1186/s12944-016-0344-y · DOI
  113. Marwarha, 2010, Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices, J. Alzheimers Dis., 19, 1007, 10.3233/JAD-2010-1298 · DOI
  114. Prasanthi, 2009, Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells, Mol. Neurodegener., 4, 1, 10.1186/1750-1326-4-1 · DOI
  115. Marwarha, 2012, Endoplasmic reticulum stress-induced CHOP activation mediates the down-regulation of leptin in human neuroblastoma SH-SY5Y cells treated with the oxysterol 27-hydroxycholesterol, Cell. Signal., 24, 484, 10.1016/j.cellsig.2011.09.029 · DOI
  116. Wirth, 2013, Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people, JAMA Neurol., 70, 1512
  117. Teune, 2010, Typical cerebral metabolic patterns in neurodegenerative brain diseases, Mov. Disord., 25, 2395, 10.1002/mds.23291 · DOI
  118. von Bohlen und Halbach, 2006, The CNS renin-angiotensin system, Cell Tissue Res., 326, 599, 10.1007/s00441-006-0190-8 · DOI
  119. Olsson, 2017, Can LDL cholesterol be too low? Possible risks of extremely low levels, J. Intern. Med., 281, 534, 10.1111/joim.12614 · DOI
  120. Michikawa, 1999, Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death, J. Neurochem., 72, 2278, 10.1046/j.1471-4159.1999.0722278.x · DOI
  121. Lutjohann, 2000, Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients, J. Lipid Res., 41, 195, 10.1016/S0022-2275(20)32052-6 · DOI
  122. Bretillon, 2000, Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface, J. Lipid Res., 41, 840, 10.1016/S0022-2275(20)32393-2 · DOI
  123. Subtil, 1999, Acute cholesterol depletion inhibits clathrin-coated pit budding, Proc. Natl. Acad. Sci. U. S. A., 96, 6775, 10.1073/pnas.96.12.6775 · DOI
  124. Wang, 2008, ATP-binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain, FASEB J., 22, 1073, 10.1096/fj.07-9944com · DOI · Paper page
  125. Frank, 2008, Cholesterol depletion inhibits synaptic transmission and synaptic plasticity in rat hippocampus, Exp. Neurol., 212, 407, 10.1016/j.expneurol.2008.04.019 · DOI
  126. Moutinho, 2015, Cholesterol 24S-Hydroxylase overexpression inhibits the liver X receptor (LXR) pathway by activating small guanosine triphosphate-binding proteins (sGTPases) in neuronal cells, Mol. Neurobiol., 51, 1489, 10.1007/s12035-014-8828-0 · DOI
  127. Lutjohann, 2004, High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs, Steroids, 69, 431, 10.1016/j.steroids.2004.03.012 · DOI
  128. Cao, 2007, Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer’s disease therapeutics, Curr. Alzheimer Res., 4, 179, 10.2174/156720507780362173 · DOI · Paper page
  129. Bigini, 2010, Neuropathologic and biochemical changes during disease progression in liver X receptor beta-/- mice, a model of adult neuron disease, J. Neuropathol. Exp. Neurol., 69, 593, 10.1097/NEN.0b013e3181df20e1 · DOI
  130. Shepardson, 2011, Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations, Arch. Neurol., 68, 1385, 10.1001/archneurol.2011.242 · DOI
  131. Rossor, 1980, Arginine vasopressin and choline acetyltransferase in brains of patients with Alzheimer type senile dementia, Lancet, 2, 1367, 10.1016/S0140-6736(80)92428-9 · DOI
  132. Casserly, 2004, Convergence of atherosclerosis and Alzheimer’s disease: inflammation, cholesterol, and misfolded proteins, Lancet, 363, 1139, 10.1016/S0140-6736(04)15900-X · DOI · Paper page
  133. Ohrui, 2004, Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression, Neurology, 63, 1324, 10.1212/01.WNL.0000140705.23869.E9 · DOI
  134. Athyros, 2014, Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease, Curr. Pharm. Des., 20, 6299, 10.2174/1381612820666140620115756 · DOI
  135. Ballas, 2005, REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis, Cell, 121, 645, 10.1016/j.cell.2005.03.013 · DOI · Paper page
  136. Ghosal, 2016, A randomized controlled study to evaluate the effect of bexarotene on amyloid-beta and apolipoprotein E metabolism in healthy subjects, Alzheimers Dement. N. Y. (N Y), 2, 110, 10.1016/j.trci.2016.06.001 · DOI · Paper page
  137. Park, 2017, Distinct roles of transcription factors KLF4, Krox20, and peroxisome proliferator-activated receptor gamma in Adipogenesis, Mol. Cell. Biol., 37, 10.1128/MCB.00554-16 · DOI
  138. Chen, 2013, Cholesterol efflux is differentially regulated in neurons and astrocytes: implications for brain cholesterol homeostasis, Biochim. Biophys. Acta, 1831, 263, 10.1016/j.bbalip.2012.09.007 · DOI · Paper page
  139. Suzuki, 2007, Brain-derived neurotrophic factor regulates cholesterol metabolism for synapse development, J. Neurosci., 27, 6417, 10.1523/JNEUROSCI.0690-07.2007 · DOI
  140. Cedazo-Minguez, 2001, Regulation of apolipoprotein E secretion in rat primary hippocampal astrocyte cultures, Neuroscience, 105, 651, 10.1016/S0306-4522(01)00224-X · DOI
  141. Jones, 2013, Alzheimer disease: TREM2 linked to late-onset AD, Nature reviews, Neurology, 9, 5
  142. Chan, 2015, CD33 modulates TREM2: convergence of Alzheimer loci, Nat. Neurosci., 18, 1556, 10.1038/nn.4126 · DOI · Paper page
  143. Thirumangalakudi, 2008, High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice, J. Neurochem., 106, 475, 10.1111/j.1471-4159.2008.05415.x · DOI · Paper page
  144. Bensinger, 2008, Integration of metabolism and inflammation by lipid-activated nuclear receptors, Nature, 454, 470, 10.1038/nature07202 · DOI
  145. Mast, 2015, Marketed drugs can inhibit cytochrome P450 27A1, a potential new target for breast Cancer Adjuvant therapy, Mol. Pharmacol., 88, 428, 10.1124/mol.115.099598 · DOI
  146. Zhang, 2018, Increased levels of 27-Hydroxycholesterol induced by dietary cholesterol in brain contribute to learning and memory impairment in rats, Mol. Nutr. Food Res., 62, 10.1002/mnfr.201700531 · DOI
  147. Mast, 2017, In vitro cytochrome P450 46A1 (CYP46A1) activation by neuroactive compounds, J. Biol. Chem., 292, 12934, 10.1074/jbc.M117.794909 · DOI
  148. Hudry, 2010, Adeno-associated virus gene therapy with cholesterol 24-Hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer’s disease, Mol. Ther., 18, 44, 10.1038/mt.2009.175 · DOI
  149. Boussicault, 2016, CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington’s disease, Brain, 139, 953, 10.1093/brain/awv384 · DOI

Cited by

Sorted by citations

Metadata

Authors
Loera-Valencia, R., Goikolea, J., Parrado-Fernandez, C., Merino-Serrais, P., & Maioli, S.
ORCID
Loera-Valencia, Raúl
Venue
The Journal of Steroid Biochemistry and Molecular Biology
Publisher
Elsevier BV
Published
2019-06
Volume
190
Pages
104-114
ISSN
0960-0760
DOI
10.1016/j.jsbmb.2019.03.003
Cited by
214
References
23
Language
en
Licence
Funders
  • Margaretha Af Ugglas Foundation, Stonhes Foundation and Foundation of Old Servants, the Swedish Medical Foundation
  • Lindhés Advokatbyrå AB Foundation
  • Karolinska Institutet Foundation for Research
  • Swedish Research Council and StratNeuro

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review